Every material Form 8-K Candel Therapeutics, Inc. has filed with the SEC since August 13, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Candel Therapeutics expanded its Board from ten to eleven directors and appointed Martine Zimmermann, Pharm.D., as an independent director effective September 8, 2026. The company said her regulatory and quality expertise supports its planned Biologics License Application submission for aglatimagene besadenovec in the fourth quarter of 2026.
Board size increased from ten to eleven directors; Zimmermann appointed September 6, 2026, effective September 8, 2026
Zimmermann receives an option to purchase 64,000 shares of common stock, vesting in equal monthly installments over three years
Annual Board retainer of $40,000, paid quarterly in arrears and pro-rated for days served
Zimmermann is Executive Vice President at Inventiva S.A. and a director of Nasdaq-listed Ligand Pharmaceuticals since October 2023
Candel Therapeutics furnished a September 2026 corporate presentation under Regulation FD, for use with investors and analysts. The deck restates Phase 3 results for aglatimagene in localized, intermediate- to high-risk prostate cancer, including extended follow-up data presented at AUA 2026, and reports cash and cash equivalents of $201.6 million as of June 30, 2026. The filing contains no new financial results or guidance.
Phase 3 trial (n=745) met its primary endpoint of disease-free survival, with a hazard ratio of 0.70 (95% CI 0.52 to 0.94; P=0.0155) in the intent-to-treat population.
Extended follow-up data (data cutoff March 15, 2026) showed prostate cancer-specific DFS hazard ratio of 0.61 (95% CI 0.44 to 0.85; P=0.0031).
Cash and cash equivalents were $201.6 million as of June 30, 2026, with expected runway into Q1 2028.
Financing includes a term loan facility with Trinity Capital of up to $130 million (October 2025) and a $100 million royalty funding agreement with RTW Investments (February 2026), subject to approval of aglatimagene in localized prostate c
Candel Therapeutics reported a second-quarter 2026 net loss of $38.9 million, up from $4.8 million a year earlier, as research and development and general and administrative expenses rose and warrant liability fair value changes added $12.2 million of other expense. The company said its $201.6 million in cash and cash equivalents as of June 30, 2026, is expected to fund operations into the first quarter of 2028, and it plans to submit a BLA for aglatimagene in localized prostate cancer in the fourth quarter of 2026.
Q2 2026 net loss was $38.9 million, or $0.52 per share, versus a net loss of $4.8 million, or $0.09 per share, in Q2 2025
R&D expenses rose to $19.8 million from $7.0 million, and G&A expenses rose to $6.9 million from $4.2 million
Cash and cash equivalents were $201.6 million at June 30, 2026, compared with $119.7 million at December 31, 2025
Planned BLA submission for aglatimagene in localized prostate cancer is expected in Q4 2026
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Candel Therapeutics, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →